Generic Asmanex Twisthaler Availability

See also: Generic Asmanex HFA

Asmanex Twisthaler is a brand name of mometasone, approved by the FDA in the following formulation(s):

ASMANEX TWISTHALER (mometasone furoate - powder;inhalation)

Has a generic version of Asmanex Twisthaler been approved?

No. There is currently no therapeutically equivalent version of Asmanex Twisthaler available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Asmanex Twisthaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Inhaler for powdered medications having spiral deagglomeration chamber
    Patent 5,687,710
    Issued: November 18, 1997
    Inventor(s): Ambrosio; Thomas J. & Bilanin; Alan J. & Kaufman; Andrew E. & Kenyon; David J. & Manthena; Srinivas & Yang; Tsong-Toh
    Assignee(s): Schering Corporation
    A powder dispenser includes a powder housing for holding a supply of powdered material to be dispensed, the powder housing including an inhalation conduit provided displaced relation to the powdered material supply; a metering plate including a metered dose hole for holding a metered amount of the powdered material, and positioned below the powdered material supply, the metering plate and the powder housing being relatively rotatable with respect to each other about a common central axis; a counter providing a visual count of the number of doses of the powdered material that have been dispensed or remain to be dispensed in response to the relative rotation, the counter including counter rings providing the visual count, the counter rings being rotatable about the common central axis and having indicia thereon which display the visual count, and an actuating mechanism rotatable about the central axis for incrementally rotating the counter rings in response to the relative rotation; a nozzle for breaking up agglomerates of powdered material from the inhalation conduit to form micronized powdered material, the nozzle including a cavity for changing the direction of flow of the powder from the direction of the inhalation conduit to a second different direction, and a curved wall for substantially continuously changing the direction of flow of the powder in a spiral manner in the second direction in the cavity; and a closure cap covering the powder housing and priming the powder dispenser for use automatically upon removal thereof.
    Patent expiration dates:
    • November 18, 2014
      ✓ 
      Drug product
    • May 18, 2015
      ✓ 
      Pediatric exclusivity
  • Inhaler for powdered medications
    Patent 5,829,434
    Issued: November 3, 1998
    Inventor(s): Ambrosio; Thomas J. & Ashley; Charles R. & Bilanin; Alan J. & Huck; Charles M. & Kaufman; Andrew E. & Kenyon; David J. & Manthena; Srinivas & Sochon; Henry R. & Wilkinson; Ken & Yang; Tsong-Toh
    Assignee(s): Schering Corporation
    A powder inhaler comprising: a powder housing for holding a supply of powdered material to be dispensed and a metering plate for holding a metered amount of said powdered material, the metering plate being alternately positionable below said supply of powdered material or within an inhalation conduit, by means of a bi-directional, angle-limited relative rotation about a common central axis; a counter for providing a visual count of the number of doses of said powdered material that have been dispensed or remain to be dispensed in response to the relative rotation, the counter including: a continuous counter ring and a coaxially mounted intermittent counter ring, both rings being mounted on a base in surrounding relation to a retaining post, being rotatable about the common central axis and having counting indicia thereon for displaying said visual count; and a display means through which at least one of the counting indicia is displayed to indicate a count corresponding to a number of doses of powdered material that have been dispensed or remain to be dispensed.
    Patent expiration dates:
    • November 3, 2015
      ✓ 
      Drug product
    • May 3, 2016
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating lower airway passage and lung diseases
    Patent 5,889,015
    Issued: March 30, 1999
    Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,057,307
    Issued: May 2, 2000
    Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
      ✓ 
      Drug product
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Powdered medication inhaler
    Patent 6,240,918
    Issued: June 5, 2001
    Inventor(s): Ambrosio; Thomas J. & Benson, Jr.; Warren A. & Dao; Kim C. & Kenyon; David J. & Kreiseder; Walter J. & Schonebaum; Theodore J. & Vogel; Allen J. & Walker; Louis B. & Yang; Tsong-Toh
    Assignee(s): Schering Corporation
    A powder dispenser includes a reservoir body including a supply of powder and an inhalation conduit; a driving body for rotating the reservoir body and including upper recesses and two spring fingers in lower driving recesses thereof; a rotatable metering plate for carrying a metered amount of powder from the supply to the inhalation conduit, and having an underside with ribs; a gas permeable retainer welded to the ribs; a spring biasing the metering plate toward the reservoir body; a nozzle having spiked ribs welded in the upper recesses of the driving body and including a chimney with vertical flutes; an adapter non-rotatably mounted with respect to the metering plate and including two locking recesses for receiving the spring fingers for locking engagement and two helical cam tracks with a square cross-section; a closure cap covering the driving body and including priming ribs biasing the spring fingers out of the locking recesses and engaging with the locking recesses to rotate the driving body, and two cams riding within the cam tracks; a base non-rotatably connected with the metering plate; and a counter rotatably mounted on the base and including rotatable counter rings providing a visual count of the number of doses of powder to be dispensed, and a pawl assembly engaging with gear teeth of the counter rings for rotating the same, the pawl assembly including an outer wall, a pawl and a pawl spring integrally molded as a single piece.
    Patent expiration dates:
    • February 20, 2017
      ✓ 
      Drug product
    • August 20, 2017
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,365,581
    Issued: April 2, 2002
    Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Preparation of powder agglomerates
    Patent 6,503,537
    Issued: January 7, 2003
    Inventor(s): Tsong-Toh; Yang
    Assignee(s): Schering Corporation
    The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
    Patent expiration dates:
    • March 17, 2018
      ✓ 
      Drug product
    • September 17, 2018
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,677,322
    Issued: January 13, 2004
    Inventor(s): Joel A.; Sequeira & Francis M.; Cuss & Keith B.; Nolop & Imtiaz A.; Chaudry & Nagamani; Nagabhushan & James E.; Patrick & Mitchell; Cayen
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Use of mometasone furoate for treating airway passage and lung diseases
    Patent 6,949,532
    Issued: September 27, 2005
    Inventor(s): Sequeira; Joel A. & Cuss; Francis M. & Nolop; Keith B. & Chaudry; Imtiaz A. & Nagabhushan; Nagamani & Patrick; James E. & Cayen; Mitchell
    Assignee(s): Schering Corporation
    The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
    Patent expiration dates:
    • January 27, 2014
      ✓ 
      Patent use: TREATMENT OF ASTHMA
    • July 27, 2014
      ✓ 
      Pediatric exclusivity
  • Preparation of powder agglomerates
    Patent 8,173,172
    Issued: May 8, 2012
    Inventor(s): Yang; Tsong-Toh
    Assignee(s): Schering Corporation
    The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing.
    Patent expiration dates:
    • March 17, 2018
      ✓ 
      Drug product
    • September 17, 2018
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)